Larger randomized control trials between insulin and the biguanide or thiazolidinedione class of agents with potential anti-inflammatory activity should be considered as alternative therapy to insulin, especially in light of consistently poor clinical outcomes reported for insulin therapy in the CF patient population. The gene discussed is INS; the disease is cystic fibrosis.